AU2002235141A1 - Glycosyltransferase vectors for treating cancer - Google Patents

Glycosyltransferase vectors for treating cancer

Info

Publication number
AU2002235141A1
AU2002235141A1 AU2002235141A AU3514102A AU2002235141A1 AU 2002235141 A1 AU2002235141 A1 AU 2002235141A1 AU 2002235141 A AU2002235141 A AU 2002235141A AU 3514102 A AU3514102 A AU 3514102A AU 2002235141 A1 AU2002235141 A1 AU 2002235141A1
Authority
AU
Australia
Prior art keywords
glycosyltransferase
vectors
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235141A
Inventor
Michael J. Schiff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU2002235141A1 publication Critical patent/AU2002235141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01087—N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002235141A 2000-11-27 2001-11-26 Glycosyltransferase vectors for treating cancer Abandoned AU2002235141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25339500P 2000-11-27 2000-11-27
US60/253,395 2000-11-27
PCT/US2001/044306 WO2002042468A2 (en) 2000-11-27 2001-11-26 Glycosyltransferase vectors for treating cancer

Publications (1)

Publication Number Publication Date
AU2002235141A1 true AU2002235141A1 (en) 2002-06-03

Family

ID=22960093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235141A Abandoned AU2002235141A1 (en) 2000-11-27 2001-11-26 Glycosyltransferase vectors for treating cancer

Country Status (3)

Country Link
US (1) US6713055B2 (en)
AU (1) AU2002235141A1 (en)
WO (1) WO2002042468A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655827B (en) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 Novel use of adenoviruses and nucleic acids coding therefor
DK1549353T3 (en) 2002-10-09 2010-07-12 Central Iowa Health System Use of alpha (1,3) galactosyltransferase expressing allogeneic tumor cells for vaccination against tumors
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
MXPA05004074A (en) * 2002-10-15 2005-09-20 Sonne Holm Per Adenovirus expressing genes in reverse order and use thereof.
US7153650B2 (en) 2003-03-13 2006-12-26 Geron Corporation Marker system for preparing and characterizing high-quality human embryonic stem cells
US7598077B2 (en) 2003-06-05 2009-10-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for enhancing differential expression
US7662101B2 (en) * 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
ES2732623T3 (en) 2005-01-06 2019-11-25 Innate Pharma Sa Anti-KIR combination treatments and methods
US8658778B2 (en) * 2005-03-09 2014-02-25 Board Of Regents, The University Of Texas System hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US9040050B2 (en) 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
JP2012503471A (en) 2008-05-30 2012-02-09 グライコフィ， インコーポレイテッド Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
ES2605677T3 (en) * 2009-11-11 2017-03-15 Momenta Pharmaceuticals, Inc. Chinese hamster glycosyltransferase and related methods
CN103003307B (en) 2010-03-10 2017-08-11 根马布股份公司 Anti- c MEt monoclonal antibody
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
DK2580243T3 (en) 2010-06-09 2020-01-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
JP6055404B2 (en) 2010-06-15 2016-12-27 ゲンマブ エー／エス Human antibody drug conjugates against tissue factor
CN103796677B (en) 2011-04-20 2019-08-16 健玛保 For the bispecific antibody of HER2 and CD3
CN103796678B (en) 2011-04-20 2018-02-27 健玛保 For HER2 bispecific antibody
WO2016089610A1 (en) 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
WO2018156434A1 (en) 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Tim3-binding chimeric antigen receptors
BR112020013954A2 (en) 2018-01-09 2020-12-01 H. Lee Moffitt Cancer Center And Research Institute Inc. compositions and methods for targeting cancers that express clec12a
EP4069245A1 (en) 2019-12-02 2022-10-12 Celgene Corporation Therapy for the treatment of cancer
US11826386B2 (en) 2020-05-05 2023-11-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
WO1989009271A1 (en) 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
US5997859A (en) 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5068191A (en) 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP1621627A3 (en) 1993-03-16 2006-06-07 The Austin Research Institute Use of porcine gala (1,3) galactosyl transferase in xenograft therapies
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
AU6691496A (en) 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
AUPN912396A0 (en) * 1996-04-03 1996-05-02 St. Vincent's Hospital (Melbourne) Limited Complement mediated rejection of transfected tumour cells
US6183993B1 (en) * 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
KR20000048820A (en) 1996-10-01 2000-07-25 게론 코포레이션 Telomerase reverse transcriptase
US5869035A (en) * 1996-11-13 1999-02-09 Human Gene Therapy Research Institute Methods and compositions for inducing complement destruction of tissue
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
AU1585999A (en) * 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
AU1606999A (en) 1997-11-26 1999-06-15 Albert Einstein College Of Medicine Of Yeshiva University Mouse telomerase reverse transcriptase
DE19757984A1 (en) 1997-12-24 1999-07-01 Bayer Ag Regulatory DNA sequences from the 5 'region of the gene of the human catalytic telomerase subunit and their diagnostic and therapeutic use
EP1147181B1 (en) 1999-02-04 2004-05-12 Geron Corporation Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
WO2001088096A2 (en) 2000-05-15 2001-11-22 Geron Corporation Ovine tissue for xenotransplantation

Also Published As

Publication number Publication date
US6713055B2 (en) 2004-03-30
WO2002042468A2 (en) 2002-05-30
WO2002042468A3 (en) 2002-11-21
US20020128221A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AU2002235141A1 (en) Glycosyltransferase vectors for treating cancer
AU2001227966A1 (en) Methods for treating tumors
AU2002324574A1 (en) Methods for treating prostatitis
HK1083771A1 (en) Anti-neovasculature preparations for cancer
AU2001293150A1 (en) Electromagnetic antenna apparatus
AU2001245283A1 (en) Methods for treating aneurysms
AU2001255602A1 (en) Methods for treating bone tumors
AUPR395801A0 (en) Antibodies against cancer
EP1176964B8 (en) Uses of et743 for treating cancer
AU6352101A (en) Apparatus for electromagnetic spectroscopy
AU2001290860A1 (en) Spas-1 cancer antigen
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU2001232054A1 (en) Vector
AUPR152100A0 (en) Method for treating coral
AU2002308642A1 (en) Methods for treating cancer
AU2001253836A1 (en) Method of treating cancer
AU2002236517A1 (en) Targetet retoviral vectors for cancer immunotherapy
AU2002257458A1 (en) Mage-a1 peptides for treating or preventing cancer
AU2001236470A1 (en) Ovarian tumor-associated sequences
AU2001294866A1 (en) Transferases
AU2001257325A1 (en) Cancer treatment
AU7936898A (en) Vectors for treating cancer
AU4672401A (en) Vectors
AU3427800A (en) Process for preparing cross-linked polyolefins